硫酸镁静脉滴注联合左旋多巴治疗帕金森氏病症状波动的临床研究  

Clinical studies of mgso4 as add-on to levodopa therapy in Parkinson’disease with motor fluctuations

作　　者：杨宁[1] 蒲蜀湘[1] 高聪[1] 

机构地区：[1]广州医学院第二附属医院神经内科,广东广州510260

出　　处：《国际医药卫生导报》2006年第17期120-121,123,共3页International Medicine and Health Guidance News

摘　　要：目的探讨硫酸镁静脉滴注治疗帕金森氏病(PD)症状波动的疗效和安全性。方法对56例长期服用左旋多巴等治疗帕金森氏病药物后出现症状波动的患者,加用25%硫酸镁10ml静脉滴注,每日1次,疗程为4周。分别在硫酸镁治疗后2、3、4周对患者进行了UPDRS(帕金森病统一评分量表)运动评分,并观察治疗期间药物的毒副作用。结果56例PD患者在硫酸镁治疗后2、3、4周UPDRS运动评分分别为(23.6±8.6)、(21.7±6.3)和(22.5±6.4),与治疗前(36.4±8.7)比较,差异均具有显著性意义(秩和检验,P<0.01)。明显运动功能显著意义(P>0.05)治疗4周后,有86.7%(48/56)的患者的运动改善程度超过20%。病人对硫酸镁耐受性好,治疗期间没有观察到明显的毒副作用。结论对长期服用左旋多巴出现症状波动或疗效减退的PD患者,加用硫酸镁治疗,能在一定程度上改善患者的运动功能。但硫酸镁治疗对PD疾病的演变是否有影响以及硫酸镁的远期疗效尚需进行了长期的观察研究。Objective To evaluate the safety and efficacy of mgso4treatment for persons with Parkinson＇s disease. Methods fifty-six Parkinson＇s disease patients with a fluctuating response to Levodopa were studied. Patients receiverd 25% mgso4 10ml （used as add-on agent to the previous medication regimen） by Ⅳ Infusion daily after two independent baseline functional assessments, Unified Parkinson＇s disease Rating scale （UPDRS） motor score for 4 weeks. After 2,3 or 4 weeks of treatment, their UPDRS motor score was re-exemined. The adverse events of mgso4 during treatment was observed. Results There was a significant improvements in patients with mgso4 treament on UPDRS motor scores （at week 2 （23.5 ± 8.9）, week 3（22.8 ± 8.3） and weed 4（22.5 ± 9.1））, as compared with that （36.5 ± 10.2） befor mgso4 therapy （rank sum test, p 〈 0.01 ）. The ADL portion of the UPDRS also showed sinificant improvements in mgso4-treated patients （at week 2 （23.6 ± 8.6）,week 3 （21.7± 6.3） and week 4 （22.5 ± 6. 4）, in compansion with the baseling （36.4 ± 8.7） （P 〈 0. 01） .I mprovements on at least some functional measures began after 2 weeks of mgso4 treatment. When functional improvements occurred, they lasted for the duration of the study. All mgso4-treated patients showed at least some improvements on UPDRS motor scores compared with baseline, with 86.7% （48 of 56 patients） improving more than 20%. Mgso4 was well tolerated and no adverse events were observed. Conclusions The study demonstrates that mgso4 treatment enhances neurologic function significantly in PD patients with a fluctuation response to levodopa. Long-term study of PD patients using mgso4 is necessary to determne whether there are any effects of mgso4 treatment on disease progression and to verify the long-term safety and effects of mgso4 use.

关 键 词：帕金森氏病 左旋多巴 硫酸镁 

分 类 号：R742.5[医药卫生—神经病学与精神病学]